Sepsis is a life-threatening syndrome characterized by a dysregulated host response to an infection resulting in multiple organ dysfunctions. Early diagnosis and management of sepsis is key to improve patient outcome but remains challenging. Despite extensive research, only few biomarkers have so far proven to be helpful in the diagnosis of sepsis. A novel protein biomarker, the pancreatic stone protein (PSP), is showing great promises. Several lines of evidences suggest that PSP has a higher diagnostic performance for the identification of sepsis than procalcitonin and C-reactive protein, and a strong prognostic value to predict unfavorable outcome at admission to intensive care unit. This review summarizes the current knowledge on the molecular mechanisms of PSP function and the clinical evidences available to highlight the relevance of this protein in the diagnosis and prognosis of sepsis.
The relative performance of each biomarker's parameter has been evaluated semiquantitatively on a scale going from '-', interpreted as 'not effective', to '++++', interpreted as 'very effective', based on published literature and the author's experience with these biomarkers. Time window of expression upon infection relates to the entire cycle of expression and clearance of the marker. CE: 'Conformité Européenne'; CRP: C-reactive protein; N.D: Not determined; PCT: Procalcitonin; PSP: Pancreatic stone protein.
roles of this protein have not been clearly elucidated, although structural homologies have been characterized to date: PSP is a globular polypeptide, which adopts the overall fold described for C-type lectins [21] , which are calcium-dependent glycan-binding proteins known to have a diverse range of functions, including adhesion and signaling receptors in homeostasis and innate immunity, and are crucial in inflammatory responses and leukocyte and platelet trafficking [22] . The first function described for PSP was the inhibition of the growth and nucleation of calcium carbonate crystals in the pancreatic juice. Pancreatic juice is indeed characterized by high concentrations of calcium and carbonate ions, which can form pancreatic stones and calcium deposits in the pancreas, as in the case of chronic pancreatitis. As subsequent functional studies have brought conflicting results, it is nowadays a matter of debate whether PSP really plays a role in this function (discussed in [23] ) . PSP has also been associated with pathological changes occurring in the pancreas during pancreatic inflammation [24] and, upon tryptic cleavage, with a calcium-and pH-dependent bacterial binding to proteoglycan [25] .
PSP levels were shown to be slightly higher in patients with Type-2 diabetes mellitus compared with healthy individuals [26] . This level is even significantly higher in the subset of patients with diabetic kidney disease, a major complication of diabetes, and an important cause of end-stage renal disease [27] .
A pivotal observation was made serendipitously in rat experiments by the group of Rolf Graf in which PSP was found to be an indicator of systemic stress [28] . This observation was then clinically confirmed in a cohort of trauma patients, in which serum PSP rises early after trauma for those patients that later develop infection and sepsis [29] . Reding et al. further showed that the pancreas senses remote organ damage and systemic stress and responds by secreting PSP, particularly when associated with septic complications [30] .
Interestingly, incubation of whole blood from healthy volunteers in presence of recombinant PSP results in a dose-dependent increase of CD11b (a mediator of inflammation) and a decrease of CD62L (a transmembrane glycoprotein, which rapidly sheds from the cell surface upon activation) on polymorphonuclear neutrophil [29] . Yet it remains uncertain whether there is a direct interaction with a membrane-bound receptor as binding of PSP required a high concentration. This indicates that PSP might require a binding partner that subsequently induces activation of signaling pathways participating in the early events of the host response to pathogens.
Preclinical data showing that PSP might activate polymorphonuclear neutrophil, promote bacterial aggregation, being involved in the host response to pathogens via its C-type lectin domain, prompted its identification as potential biomarker for sepsis. Moreover, the observation that PSP level rose in response to septic insults in mice and rats encouraged its clinical evaluation as biomarker of sepsis in various settings and conditions.
Diagnostic & prognostic performance of PSP in sepsis
PSP has been studied and compared with other biomarkers in various settings of infections and sepsis, both as a diagnostic marker of infection and/or sepsis, or a prognostic marker of disease outcome ( Table 2 ). All studies available at the time of preparation of this review have been done using the former Sepsis-2 criteria. It is likely (and desired) that ongoing and future studies will be done following the Sepsis-3 criteria.
In 12 out of 13 studies among various clinical settings (ED, ICU, surgical, nonsurgical adult and children), PSP proved to be more accurate, with a higher sensitivity, specificity, positive and negative predictive values than CRP, PCT, IL-6 and other cytokines for the diagnosis of sepsis and prognosis of unfavorable outcome. In all these studies, PSP levels well correlated with disease severity, ranging from <20 ng/ml in adult patients without infection to several hundred nanogram/milliliter in patients with severe sepsis and even several thousand nanograms/milliliters in the case of septic shock ( Table 2) . A unique characteristic of PSP is that it may start to increase above the normal level range before the development of clinical signs and symptoms of sepsis. In a pivotal study, serial PSP measurements in multiple trauma patients were able to identify patients who were developing a sepsis before the rise of other biomarkers, and before the clinical diagnostic, in most cases [29] . The same has been reported in patients after cardiac surgery. In all 120 patients PSP levels raised after elective cardiac surgery, independently from the characteristics of surgery, but was significantly higher postoperatively, at 24, 48 and 72 h among the 18 patients (15%) developing an infectious complication [34] .
In a population of patients with sepsis-related complications, PSP levels have demonstrated a high diagnostic accuracy to discriminate the severity of peritonitis and to predict death in the ICU [33] . In another study, PSP levels reflected organ dysfunction and predicted death in ventilator-associated pneumonia (VAP), which allowed stratifying patients with good and poor outcome [36] . The value of PSP to predict in-hospital mortality in patients with severe sepsis and septic shock requiring ICU management has been further demonstrated by Que et al. [37] , who also highlighted in another research that a model combining severity scores with PCT and PSP improves mortality prediction in these patients [38] . The clinical accuracy of PSP to identify sepsis and multiple organ dysfunction was also confirmed in a cohort of unselected, heterogeneous patients admitted to intensive or high-dependency care unit [32] , as well as on a cohort of patients presenting to ED with suspicion of infection [35] .
Data on the diagnostic performance of PSP for sepsis are also available for children and neonates. In children, the combination of PSP, PCT and CRP was superior to each of the individual markers for the risk stratification of pediatric sepsis [42] , and the combination of PSP and PCT had significantly higher diagnostic accuracy for osteomyelitis than that of PSP or PCT alone [43] . In neonates, a population particularly at risk of sepsis and associated with high morbidity and mortality, a high negative predictive value of PSP, alone or in combination with PCT was found for early onset neonatal sepsis, which supports the concept of using PSP to rule out sepsis and thereby safely reduce antibiotic treatment in this specific population [39, 40] .
Potential use of PSP in clinical diagnosis & management of sepsis & the need for short turnaround time
The potential for the use of PSP alone or in combination with other sepsis biomarkers, especially CRP and PCT, is promising. The higher accuracy of PSP in the diagnosis of sepsis, its good correlation with the severity of organ failures and its unique prognostic value strongly argue for its use in the clinical setting ( Table 2 ).
• PSP may be used to confirm the early suspicion of sepsis. PSP may thus allow reducing poorly justified 'emotional prescriptions' of antibiotic, a major goal of antibiotic stewardship programs; • PSP may be used to stratify patients early according to disease severity, alone or in combination with routine severity scores such as APACHE II, SAPS II and SOFA; • PSP may be used to stratify patients early according to prognosis and outcome, and thus allow correct triage and further management; • PSP may ease screening and inclusion of septic patients in clinical trials.
Diagnosis of sepsis is especially challenging as the clinical signs and symptoms are not specific; most of the time a large overlap exists with noninfective causes of systemic inflammation. As early treatment of sepsis is associated with improved outcomes, rapid identification is key -every hour of delayed treatment represents increasing mortality [44] .
High suspicion based on markers immediately available to the clinicians, such as body temperature, heart and respiratory rates, acute alteration of mental function and low blood pressures are neither sufficiently specific nor sensitive enough, even if used in combination as part of a clinical score [45] . Therefore, these scoring systems should be complemented with other parameters to improve their prognostic and/or diagnostic performances. In respect to that, blood host protein biomarkers represent certainly a promising approach, if (and only if ) available within minutes to the clinicians.
Availability of PSP results within minutes from a drop of whole blood may bring a real breakthrough in the management of patients with sepsis or at risk of developing a sepsis. POCT has made tremendous progress in recent years and is today already commonly used for several applications in ED and ICU, such as for the bedside serial Sample is mixed with a detecting reagent and deposited at the entrance of a nanofluidic biosensors. The concentration of analyte is proportional to the fluorescence emitted by the detecting antibody label with a fluorophore. Reproduced with permission from [46] C Springer Nature (2018). measurement of blood gas, lactate, electrolytes or glucose. Implementing a novel POCT in these clinical settings is challenging (extensive training must be conducted to ensure good practices; quality controls are performed outside the clinical laboratory; test results must be incorporated to the hospital information system; POCT are more expensive than corresponding tests on large laboratory analyzers. . . ). Therefore, advantages of using a POCT must counterbalance these limitations. This can be achieved through both proven clinical benefit of using a POCT and an economical benefit taking into consideration the entire patient stay. POCT has also an added advantage in settings where clinical laboratories cannot deliver results in the time consensually defined with clinicians, or when closed at night or weekends. New technologies are today requiring few or no preanalytical activities (to shorten hand-on time and mitigate risk of exposure of the operator to potentially biohazardous material), and have analytic performances meeting clinician's needs (in particular regarding accuracy, precision, analytical sensitivity and assay reportable range).
A recent technology based on nanofluidics (abioSCOPE, Abionic SA, Epalinges, Switzerland) allows quantifying proteins at the picomolar range from a drop of whole blood in a few minutes and without preanalytic work. Nanofluidic channels strongly influence the diffusional behavior of biomolecules and increase molecular interactions [43] . Due to the submicron structuration, the binding surface for the capture biomolecule is strongly increased, which enhances the sensitivity of the sensor and the biomolecular interaction leading to reduced assay times (Figure 1) .
This technology has been used to develop a rapid PSP test, which is currently evaluated in ICU for the earlier detection of sepsis and represents an interesting solution as it combines two key requirements: short total turnaround future science group www.futuremedicine.com time and a biomarker with high sensitivity and specificity to aid in identifying sepsis. As PSP is a biomarker giving information on urgent situations, future studies using PSP must be conducted at the bedside to clearly assess the benefit of obtaining PSP results within minutes for the management of sepsis patients and patients at risk of sepsis.
Conclusion
With an aging population worldwide, increasing prevalence of noncommunicable, chronic or serious illnesses associated with higher risk of sepsis (i.e., diabetes, obesity, malignancy. . . ) and the threat of global antimicrobial resistances, sepsis incidences are unlikely to diminish in the near future. However, on the longer term, the combination of rapid diagnostic solutions, biomarker-guided therapies and an increased awareness of sepsis in both the community and among clinicians will contribute to reduce death and long-term complications of sepsis. The promising results obtained so far with the PSP in various clinical situations support that this biomarker has the potential to contribute to a better management of sepsis.
Future perspective
Despite an improved understanding of the pathophysiology of sepsis, a worldwide recognized need of earlier detection and the clinical evaluation of hundreds of proteins, metabolites, host and pathogen genetic markers, diagnosis and prognosis of sepsis remains a daily challenge for clinicians. Recent technological advancements and the discovery of novel promising markers open new avenues for the development of fast diagnostic solutions at the bedside, using measurements of biomarkers with high diagnostic accuracy for infection, sepsis and septic shock. The agenda for further evaluation of the clinical utility of PSP should at least focus on:
• Demonstrating the impact of using PSP for: the early identification of sepsis in the ICU before the onset of typical signs and symptoms of sepsis; the prompt confirmation of sepsis in patients with clinical suspicion of infection (ICU, ED, out-patient clinic, nursing homes, ambulances. . . ); and the risk stratification of septic patients and prognostication of their outcome to facilitate triage decision; • Confirming the feasibility, clinical impact and economic benefit of serial real-time measurements of PSP in various settings, such as ICU and ED, using POCT technology (versus measurement in clinical laboratories); • Bringing robust evidence, through large randomized trials, that bedside measurement of PSP in ED or in ICU is changing clinicians' behavior; thereby improving patient health outcome and potentially, adherence to antibiotic stewardship programs without jeopardizing patient safety; • Finally, better understanding the molecular mechanisms of PSP function, in both healthy and septic patients, including a thorough understanding of the PSP kinetics (peak maximum level in presence of infection and/or sepsis and clearance upon resolution of the infection and/or organ dysfunction) and identification of medical conditions resulting in a rise of the PSP level independently of the presence of an infection or sepsis.
In addition, there are a couple of questions that need to be answered to clearly capture the potential of PSP compared with currently available biomarkers: how is PSP level evolving in patients with viral, fungal, parasitic, gram positive and negative bacteria? Is the PSP a reliable biomarker in neutropenic septic patients? What is the clinical utility of PSP for the identification of early onset neonatal sepsis, in particular in preterm babies? Are there any conditions leading to a rise of PSP levels that are not related to infection? As PSP is secreted mostly by the pancreas, could it be a marker of severity for pancreatitis? What is, if any, the clinical impact of combining PSP with other biomarkers? Would the combination of PSP with other established or new biomarkers and/or with scoring systems increase diagnostic accuracy of sepsis?
The first 5 years should allow finding answers to these specific open questions. Once the clinical utility of PSP has been confirmed within large studies, the five following years should push the PSP use outside the EDs and ICUs to more diverse patient populations and clinical situations. This is the only way to make PSP part of the standard of care.
In parallel, our better understanding of the pathophysiology of PSP in sepsis will probably allow better sorting septic patients, which may in turn improve management by selecting the intervention that suits most the patient condition.
Beside clinical research and clinical utility, the health economic benefit of measuring PSP at the point-of-care in different clinical scenario and patient populations must also be demonstrated to facilitate technology appraisal processes by national regulatory agencies.
Executive summary
• Sepsis is a global health problem worldwide, and its diagnosis is today still challenging. Current blood biomarkers, used to help clinicians diagnosing sepsis, are neither enough sensitive nor specific.
• Pancreatic stone protein (PSP) is a protein secreted by the pancreas and its response to stress induced by systemic infection and sepsis.
• Several clinical studies performed in intensive care units and in Emergency Department have shown great potential of PSP measurement for early identification of sepsis and prediction of disease outcome. In those studies, PSP was systematically performing similarly or better than procalcitonin and C-reactive protein.
• More clinical data and a better understanding of the pathophysiological mechanisms of PSP function are needed to assess the potential of PSP as a disruptive biomarker for the early diagnosis of sepsis, in adults, children and neonates.
• As sepsis is a condition that demands an urgent intervention to increase chances of favorable outcome, rapid measurement at the bedside of PSP is an interesting approach to improve identification and management of septic patients.
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